AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

RUXOLITINIB

11 registrations across 4 African markets— 8 active

Markets with RUXOLITINIB

Recent registrations

Brand / ProductMarketHolderStatusExpires
Jakavi 5mg
Tablet
🇰🇪KenyaNVS Kenya LimitedactiveSept 2030
Jakavi 15mg
Tablet
🇰🇪KenyaNVS Kenya LimitedactiveSept 2030
Jakavi 20mg
Tablet
🇰🇪KenyaNVS Kenya LimitedactiveSept 2030
JAKAVI
Comprimé / 5 mg
🇹🇳TunisiaNOVARTIS PHARMA SCHWEIZ AGexpiredApr 2019
JAKAVI
Comprimé / 15 mg
🇹🇳TunisiaNOVARTIS PHARMA SCHWEIZ AGexpiredApr 2019
JAKAVI
Comprimé / 20 mg
🇹🇳TunisiaNOVARTIS PHARMA SCHWEIZ AGexpiredApr 2019
RUXOLITINIB
ORAL SOLID ORDINARY TABLETS
🇺🇬UgandaNOVARTIS PHARMA SERVICES INCactive
RUXOLITINIB
ORAL SOLID ORDINARY TABLETS
🇺🇬UgandaNOVARTIS PHARMA SERVICES INCactive
RUXOLITINIB
ORAL SOLID ORDINARY TABLETS
🇺🇬UgandaNOVARTIS PHARMA SERVICES INCactive
Jakavi
Tablets
🇹🇿TanzaniaNVS Kenya Limitedactive
RUXOLITINIB
ORAL SOLID ORDINARY TABLETS
🇺🇬UgandaNOVARTIS PHARMA SERVICES INCactive

RUXOLITINIB in Africa — Regulatory Overview

RUXOLITINIB is registered across 4 African markets with 11 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Uganda, Kenya, Tunisia, Tanzania. AfricaRegulatory refreshes this data daily from official government sources.

Of the 11 registrations, 8 (73%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.